Literature DB >> 35319912

Strategies for Reducing False-Positive Screening Results for Intermediate-Size Nodules Evaluated Using Lung-RADS: A Secondary Analysis of National Lung Screening Trial Data.

Mark M Hammer1, Andetta R Hunsaker1.   

Abstract

BACKGROUND. Lung-RADS version 1.1 (v1.1) classifies all solid nodules less than 6 mm as category 2. Lung-RADS v1.1 also classifies solid intermediate-size (6 to < 10 mm) nodules as category 2 if they are perifissural and have a triangular, polygonal, or ovoid shape (indicative of intrapulmonary lymph nodes). Additional category 2 criteria could reduce false-positive results of screening examinations. OBJECTIVE. The purpose of this study was to evaluate the impact of proposed strategies for reducing false-positive results for intermediate-size nodules on lung cancer screening CT evaluated using Lung-RADS v1.1. METHODS. This retrospective study entailed secondary analysis of National Lung Screening Trial (NLST) data. Of 1387 solid nodules measuring 6.0-9.5 mm on baseline screening CT examinations in the NLST, all 38 nodules in patients who developed cancer and a random sample of 200 nodules in patients who did not develop cancer were selected for further evaluation. Cancers were required to correspond with the baseline nodule on manual review. After exclusions, the sample included 223 patients (median age, 62 years; 143 men, 80 women; 196 benign nodules, 27 malignant nodules). Two thoracic radiologists independently reviewed baseline examinations to record nodule diameter and volume using semiautomated software and to determine whether nodules had perifissural location; other subpleural location; and triangular, polygonal, or ovoid shape. Different schemes for category 2 assignment were compared. RESULTS. Across readers, standard Lung-RADS v1.1 had sensitivity of 89-93% and specificity of 26-31%. A modification assigning nodules less than 10 mm with triangular, polygonal, or ovoid shape in other subpleural locations (vs only perifissural location) as category 2 had sensitivity of 85-93% and specificity of 47-51%. Lung-RADS v1.1 using volume cutoffs had sensitivity of 89-93% and specificity of 37% (both readers). The sensitivity of both modified Lung-RADS v1.1 and Lung-RADS v1.1 with volume cutoffs was not significantly different from standard Lung-RADS v1.1 (all p > .05). However, both schemes' specificity was significantly better than standard Lung-RADS v1.1 (all p < .05). Combining the two strategies yielded sensitivity of 85-93% and specificity of 58-59%. CONCLUSION. Classifying intermediate-size nodules with triangular, polygonal, or ovoid shape in any subpleural (not just perifissural) location as category 2 and using volume- rather than diameter-based measurements improves Lung-RADS specificity without decreased sensitivity. CLINICAL IMPACT. The findings can help reduce false-positive results, decreasing 6-month follow-up examinations for benign findings.

Entities:  

Keywords:  false-positive; intrapulmonary lymph node; lung cancer screening; pulmonary nodule

Mesh:

Year:  2022        PMID: 35319912      PMCID: PMC9398972          DOI: 10.2214/AJR.22.27595

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   6.582


  16 in total

1.  Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support.

Authors:  Paul A Harris; Robert Taylor; Robert Thielke; Jonathon Payne; Nathaniel Gonzalez; Jose G Conde
Journal:  J Biomed Inform       Date:  2008-09-30       Impact factor: 6.317

2.  New Fissure-Attached Nodules in Lung Cancer Screening: A Brief Report From The NELSON Study.

Authors:  Daiwei Han; Marjolein A Heuvelmans; Carlijn M van der Aalst; Lisa H van Smoorenburg; Monique D Dorrius; Mieneke Rook; Kristiaan Nackaerts; Joan E Walter; Harry J M Groen; Rozemarijn Vliegenthart; Harry J de Koning; Matthijs Oudkerk
Journal:  J Thorac Oncol       Date:  2019-10-10       Impact factor: 15.609

3.  Reduced lung-cancer mortality with low-dose computed tomographic screening.

Authors:  Denise R Aberle; Amanda M Adams; Christine D Berg; William C Black; Jonathan D Clapp; Richard M Fagerstrom; Ilana F Gareen; Constantine Gatsonis; Pamela M Marcus; JoRean D Sicks
Journal:  N Engl J Med       Date:  2011-06-29       Impact factor: 91.245

4.  Cost-Effectiveness Analysis of Lung Cancer Screening in the United States: A Comparative Modeling Study.

Authors:  Steven D Criss; Pianpian Cao; Mehrad Bastani; Kevin Ten Haaf; Yufan Chen; Deirdre F Sheehan; Erik F Blom; Iakovos Toumazis; Jihyoun Jeon; Harry J de Koning; Sylvia K Plevritis; Rafael Meza; Chung Yin Kong
Journal:  Ann Intern Med       Date:  2019-11-05       Impact factor: 25.391

5.  Lung-RADS Version 1.1: Challenges and a Look Ahead, From the AJR Special Series on Radiology Reporting and Data Systems.

Authors:  Lydia Chelala; Rydhwana Hossain; Ella A Kazerooni; Jared D Christensen; Debra S Dyer; Charles S White
Journal:  AJR Am J Roentgenol       Date:  2021-01-20       Impact factor: 3.959

6.  Characterization of Newly Detected Costal Pleura-attached Noncalcified Nodules at Annual Low-Dose CT Screenings.

Authors:  Yeqing Zhu; Rowena Yip; Nan You; Qiang Cai; Claudia I Henschke; David F Yankelevitz
Journal:  Radiology       Date:  2021-09-21       Impact factor: 11.105

7.  Management of Nodules Attached to the Costal Pleura at Low-Dose CT Screening for Lung Cancer.

Authors:  Yeqing Zhu; Rowena Yip; Nan You; Claudia I Henschke; David F Yankelevitz
Journal:  Radiology       Date:  2020-10-06       Impact factor: 11.105

8.  Cancer Risk in Subsolid Nodules in the National Lung Screening Trial.

Authors:  Mark M Hammer; Lauren L Palazzo; Chung Yin Kong; Andetta R Hunsaker
Journal:  Radiology       Date:  2019-09-17       Impact factor: 11.105

9.  Lung cancer screening by nodule volume in Lung-RADS v1.1: negative baseline CT yields potential for increased screening interval.

Authors:  Mario Silva; Gianluca Milanese; Stefano Sestini; Federica Sabia; Colin Jacobs; Bram van Ginneken; Mathias Prokop; Cornelia M Schaefer-Prokop; Alfonso Marchianò; Nicola Sverzellati; Ugo Pastorino
Journal:  Eur Radiol       Date:  2020-09-30       Impact factor: 5.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.